<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050397</url>
  </required_header>
  <id_info>
    <org_study_id>Patient School 1</org_study_id>
    <nct_id>NCT04050397</nct_id>
  </id_info>
  <brief_title>Exercise and Quality of Life During Androgen Deprivation Therapy</brief_title>
  <official_title>Exercise Intervention to Reduce Adverse Quality of Life Effects From Androgen Deprivation Therapy for Prostate Cancer - Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Varalan urheiluopisto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates effects of supervised exercise in reducing adverse effects of hormonal
      treatment, increasing quality of life and in inducing a long-term change into more active
      lifestyle in prostate cancer patients on androgen deprivation therapy. All participants will
      attend a starting lecture at the beginning of the trial, after which they are randomly
      allocated to attend 3 months of either supervised or non-supervised exercise program. Leisure
      time activity, quality of life, blood sugar and cholesterol values, and body composition of
      participants will be evaluated at three time-points; at recruitment, after 12 weeks and after
      24 weeks. Effects on quality of life will also be qualitatively evaluated with single- and
      group interviews.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgen deprivation therapy (ADT) is commonly used in management of advanced or recurrent
      prostate cancer. It also frequently used adjuvant to curative-intent radiation therapy for
      localized prostate cancer. Low testosterone levels during androgen deprivation commonly cause
      adverse effects reducing quality of life. Most common adverse effects include fatigue, weight
      gain, loss of lean muscle mass, hyperglycemia and hypercholesterolemia.

      Regular exercise, especially programs involving combination of both aerobic exercise and
      resistance training has been shown to reduce to reduce adverse effects of ADT on physical
      functioning and quality of life. It may also improve disease prognosis.

      The study compares effects of supervised and unsupervised exercise on plasma lipid parameters
      (total cholesterol, LDL, HDL and triglycerides) and glucose levels (fasting plasma glucose,
      glycated hemoglobin), overall quality of life and on average daily exercise activity in men
      with prostate cancer and under ADT. As secondary outcome we will study effect on continued
      exercise activity after the intervention, changes in body composition, blood pressure and
      risk of fractures, castration resistance as well as death due to prostate cancer and due to
      any cause.

      Study hypothesis is that supervised exercise will improve quality of life, lipid and glucose
      parameters and increase daily exercise activity more that non-supervised exercise. We also
      expect higher continued exercise activity, greater changes in body composition and blood
      pressure and lowered risk of fractures and death in the supervised exercise group.

      This is a randomized, controlled clinical trial. The study aims to recruit 40 men on ADT for
      prostate cancer. This will be a pilot study to estimate effect sizes in Finnish population to
      inform further larger trial.

      All participants attend introductory lecture, where a urologist informs them about adverse
      effects of ADT and positive effects of exercise during ADT, exercise instructor gives advice
      for training both at home and in the gym and nutritional therapeutist tells about nutrition
      to overcome adverse effects of ADT and support training.

      After the introductory lecture the participants are randomized 1:1 to either the supervised
      or non-supervised exercise group (Figure). Men in the supervised group participate in
      progressive group exercise sessions twice a week for total of 12 weeks at the Varala sports
      academy in Tampere, Finland. Each exercise session includes both aerobic and resistance
      training targeting all major muscle groups (Additional document I, exercise program). The
      non-supervised group will exercise independently for 12 weeks according to the instructions
      given at the introductory lecture. The first control visit will be after this first period of
      12 weeks of exercise.

      After the first follow-up visit both group will continue non-supervised exercise for 12
      weeks, after which the second control visit will be arranged. Special focus on the second
      control visit is to see how many in each group has been able to carry on active exercising,
      i.e. has the intervention promoted long-term change in exercise activity.

      Both study group will be given Polar wrist activity monitors to be used 24 h/day for the
      entire course of the study.

      All participants are asked to fill validated quality of life surveys EORTC QLQC-30 (overall
      quality of life) and EORTC QLQC-PR25 (prostate cancer-specific quality of life) at baseline
      and again at 1st and 2nd control visits. Additionally, qualitative evaluation of quality of
      life as well as perceived possibilities and obstacles for exercise are evaluated in
      individual- and group interviews during the study visits. Plasma lipid and glucose
      parameters, blood pressure and body composition will be measured at each of these visits.

      At each visit a separate blood sample is taken and stored for future measurement of
      biomarkers associated with prostate cancer progression, glucose and lipid metabolism and
      effects of exercise.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Anticipated">August 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participant will be randomized 1:1 to either supervised exercise for 12 weeks or to follow given exercise program on their own.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily total activity</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Daily activity as measured by wrist activity monitor worn by the participants at all times during the study. Measured as metabolic equivalents of task (MET) units. Range from 0.9 to 23.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting plasma total cholesterol</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Value measure in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting plasma LDL cholesterol</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Value measure in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting plasma HDL cholesterol</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Value measure in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting plasma triglycerides</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Value measure in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting plasma glucose level</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Value measured in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood glycated hemoglobin (HbA1C) level</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Value measured in mmol/mol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall quality of life</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Score from validated survey EORTC QLQ-C30, score range from 0-100, with 100 denoting the highest quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate cancer-specific quality of life</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Score from validated survey EORTC QLQ-PR25, score range from 0-100, with 100 denoting the highest quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in daily activity after the intervention</measure>
    <time_frame>Measured daily for 12 weeks' time after the intervention</time_frame>
    <description>Change in daily activity of the supervised exercise group after completion of 12 weeks of supervised exercise as measured by wrist activity monitor in MET units, range from 0.9 to 23.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective adverse effects of castration treatment</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>The effect of supervised exercise on subjective adverse effects of castration treatment for prostate cancer. Qualitative assessment in three individual interviews and one group interview. No scaling used as this is a qualitative rather than quantitative end-point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Bioimpedance-based measurement of lean body mass as percentage of total body mass measured with TANITA MC-780 device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Bioimpedance-based measurement of muscle mass as percentage of total body mass measured with TANITA MC-780 device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal mass</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Bioimpedance-based measurement of skeletal mass as percentage of total body mass measured with TANITA MC-780 device measured with TANITA MC-780 device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Bioimpedance-based measurement of fat mass as percentage of total body mass measured with TANITA MC-780 device measured with TANITA MC-780 device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic age</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Metabolic age measured with bioimpedance-based TANITA MC-780 device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Value measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>At randomization and twice more at 12 week intervals</time_frame>
    <description>Value measured in mmHg</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to castration resistance</measure>
    <time_frame>Followed yearly for up to 15 years from randomization</time_frame>
    <description>Time to castration resistance as defined by two consecutive rising PSA levels and increase of 50% or more from the nadir. Measured as months between the study recruitment and first record of castration resistance. Information obtained from patient files.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to death</measure>
    <time_frame>Followed yearly for up to 15 years from randomization</time_frame>
    <description>Time to death due to any cause. Measured as months between the study recruitment and date of death. Information obtained from patient files and national death certificate registry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to prostate cancer death</measure>
    <time_frame>Followed yearly for up to 15 years from randomization</time_frame>
    <description>Time to death due to prostate cancer. Measured as months between the study recruitment and date of death. Information obtained from patient files and national death certificate registry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone fractures</measure>
    <time_frame>Followed yearly for up to 15 years from randomization</time_frame>
    <description>Occurrence of any bone fracture requiring either conservative or operative management. Information obtained from patient files and national hospital discharge registry. Fracture site and it's management are recorded.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Supervised exercise arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Informational initiation lecture and supervised exercise twice a week for 12 weeks followed by 12 weeks of non-supervised exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-supervised exercise arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Informational initiation lecture and only non-supervised exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Progressive supervised weight training</intervention_name>
    <description>12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.</description>
    <arm_group_label>Supervised exercise arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lecture</intervention_name>
    <description>Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.</description>
    <arm_group_label>Non-supervised exercise arm</arm_group_label>
    <arm_group_label>Supervised exercise arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing castration treatment for prostate cancer

          -  Informed consent for the study

        Exclusion Criteria:

          -  Unable to participate in exercise (ECOG 2 or greater)

          -  High bone fracture risk (as judged by the primary physician)

          -  Unable to understand spoken and written instructions in Finnish
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teemu Murtola, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampereen University, Faculty of Medicine and Health Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teemu Murtola, MD PhD</last_name>
    <phone>+358 3 311 65015</phone>
    <email>teemu.murtola@tuni.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teuvo Tammela, MD PhD</last_name>
    <phone>+358 3 311 64621</phone>
    <email>teuvo.tammela@tuni.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teemu Murtola, MD, PhD</last_name>
      <phone>+358 3 311 65015</phone>
      <email>teemu.murtola@tuni.fi</email>
    </contact>
    <contact_backup>
      <last_name>Teuvo Tammela, MD PhD</last_name>
      <phone>+358 3 311 64621</phone>
      <email>teuvo.tammela@tuni.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Lauri Rantaniemi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jarno Riikonen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanna Ojala, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilkka Pietil√§, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teuvo LJ Tammela, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>androgen deprivation therapy</keyword>
  <keyword>exercise</keyword>
  <keyword>quality of life</keyword>
  <keyword>blood glucose</keyword>
  <keyword>cholesterol</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared since it is prohibited by the ethics board and by patient consent</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT04050397/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

